These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36891710)

  • 21. Genome-wide circular RNA (circRNA) and mRNA profiling identify a circMET-miR-410-3p regulatory motif for cell growth in colorectal cancer.
    Liu Y; Chen L; Liu T; Su X; Peng L; Chen J; Tan F; Xing P; Wang Z; Di J; Jiang B; Qu H
    Genomics; 2022 Jan; 114(1):351-360. PubMed ID: 34929287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in Circular RNA and Its Applications.
    Zhao X; Zhong Y; Wang X; Shen J; An W
    Int J Med Sci; 2022; 19(6):975-985. PubMed ID: 35813288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel role of CRTC2 in promoting nonalcoholic fatty liver disease.
    Han HS; Kim SG; Kim YS; Jang SH; Kwon Y; Choi D; Huh T; Moon E; Ahn E; Seong JK; Kweon HS; Hwang GS; Lee DH; Cho KW; Koo SH
    Mol Metab; 2022 Jan; 55():101402. PubMed ID: 34838715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. miR-26a Potentially Contributes to the Regulation of Fatty Acid and Sterol Metabolism In Vitro Human HepG2 Cell Model of Nonalcoholic Fatty Liver Disease.
    Ali O; Darwish HA; Eldeib KM; Abdel Azim SA
    Oxid Med Cell Longev; 2018; 2018():8515343. PubMed ID: 30402207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease.
    Lin Y; Ding D; Huang Q; Liu Q; Lu H; Lu Y; Chi Y; Sun X; Ye G; Zhu H; Wei J; Dong S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):869-882. PubMed ID: 28483554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circular RNA as a Novel Biomarker and Therapeutic Target for HCC.
    Meng H; Niu R; Huang C; Li J
    Cells; 2022 Jun; 11(12):. PubMed ID: 35741077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Silencing lncRNA NEAT1 reduces nonalcoholic fatty liver fat deposition by regulating the miR-139-5p/c-Jun/SREBP-1c pathway.
    Jin SS; Lin CJ; Lin XF; Zheng JZ; Guan HQ
    Ann Hepatol; 2022; 27(2):100584. PubMed ID: 34808393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Altered microRNA-9 Expression Level is Directly Correlated with Pathogenesis of Nonalcoholic Fatty Liver Disease by Targeting Onecut2 and SIRT1.
    Ao R; Wang Y; Tong J; Wang BF
    Med Sci Monit; 2016 Oct; 22():3804-3819. PubMed ID: 27756894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CircLDLR acts as a sponge for miR-667-5p to regulate SIRT1 expression in non-alcoholic fatty liver disease.
    Yuan X; Li Y; Wen S; Xu C; Wang C; He Y; Zhou L
    Lipids Health Dis; 2022 Nov; 21(1):127. PubMed ID: 36443854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Revealing new landscape of cardiovascular disease through circular RNA-miRNA-mRNA axis.
    Su Q; Lv X
    Genomics; 2020 Mar; 112(2):1680-1685. PubMed ID: 31626900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Roles of microRNAs in immunopathogenesis of non-alcoholic fatty liver disease revealed by integrated analysis of microRNA and mRNA expression profiles.
    Zhang YJ; Hu Y; Li J; Chi YJ; Jiang WW; Zhang F; Liu YL
    Hepatobiliary Pancreat Dis Int; 2017 Feb; 16(1):65-79. PubMed ID: 28119261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives.
    Hochreuter MY; Dall M; Treebak JT; Barrès R
    Mol Metab; 2022 Nov; 65():101581. PubMed ID: 36028120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MiR-103-3p promotes hepatic steatosis to aggravate nonalcoholic fatty liver disease by targeting of ACOX1.
    Ding J; Xia C; Cen P; Li S; Yu L; Zhu J; Jin J
    Mol Biol Rep; 2022 Aug; 49(8):7297-7305. PubMed ID: 35606603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetics and epigenetics purpose in nonalcoholic fatty liver disease.
    Botello-Manilla AE; Chávez-Tapia NC; Uribe M; Nuño-Lámbarri N
    Expert Rev Gastroenterol Hepatol; 2020 Aug; 14(8):733-748. PubMed ID: 32552211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-coding RNA Associated Competitive Endogenous RNA Regulatory Network: Novel Therapeutic Approach in Liver Fibrosis.
    Riaz F; Li D
    Curr Gene Ther; 2019; 19(5):305-317. PubMed ID: 31696817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of 8-miRNAs as biomarkers for nonalcoholic fatty liver disease.
    Yu Y; Zhu J; Liu J; Huang M; Wan JX
    J Cell Physiol; 2019 Aug; 234(10):17361-17369. PubMed ID: 30790285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγ axis in non-alcoholic fatty liver disease.
    Liu J; Tang T; Wang GD; Liu B
    Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31064820
    [No Abstract]   [Full Text] [Related]  

  • 38. Construction of a circular RNA-based competing endogenous RNA network to screen biomarkers related to intervertebral disc degeneration.
    Yu B; Zhu Z; Hu T; Lu J; Shen B; Wu T; Guo K; Chaudhary SK; Feng H; Zhao W; Wu D
    BMC Musculoskelet Disord; 2022 Jul; 23(1):675. PubMed ID: 35840955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive identification of RNA transcripts and construction of RNA network in chronic obstructive pulmonary disease.
    Liu P; Wang Y; Zhang N; Zhao X; Li R; Wang Y; Chen C; Wang D; Zhang X; Chen L; Zhao D
    Respir Res; 2022 Jun; 23(1):154. PubMed ID: 35690768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antagonizing circRNA_002581-miR-122-CPEB1 axis alleviates NASH through restoring PTEN-AMPK-mTOR pathway regulated autophagy.
    Jin X; Gao J; Zheng R; Yu M; Ren Y; Yan T; Huang Y; Li Y
    Cell Death Dis; 2020 Feb; 11(2):123. PubMed ID: 32054840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.